Premium
IC‐P‐114: A refined cortical signature of Alzheimer's disease
Author(s) -
Wang Liang,
Ercole Lindsay,
Blazey Tyler,
Benzinger Tammie,
Hassenstab Jason,
Morris John,
Ances Beau
Publication year - 2013
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2013.05.111
Subject(s) - pittsburgh compound b , clinical dementia rating , dementia , psychology , pathology , white matter , cohort , biomarker , medicine , magnetic resonance imaging , disease , radiology , chemistry , biochemistry
symptomatic AD participants were characterized using amyloid b (Ab) imaging using Pittsburgh Compound B (PiB), cerebrospinal fluid (CSF) Ab42, tau and phosphorylated tau181. Vertex-wise comparisons were conducted between CN individuals (N1⁄4106) who were negative for all biomarkers and AD individuals (N1⁄464) who were positive for either PiB or CSF Ab42 using general linear model. Group difference map thresholded at p < 0.05 (corrected) identifies the regions showing reduced cortical thickness in AD participants. Color-coded labels derived from these regions are shown on the semi-inflated cortical surface of the Freesurfer average brain with light gray regions representing gyri and dark gray regions representing Table 1 Demographics and cerebrospinal fluid biomarkers in cognitively normal participants